Inhibition of eosinophil chemotaxis by a new antiallergic compound (cetirizine).
The in vivo inhibitory effect of a new antiallergic, anti-H1 drug, cetirizine, on eosinophil attraction at skin sites challenged with various stimuli has been recently suggested. In the present work, we confirmed that this molecule, at therapeutical concentration, has a potent inhibitory action on eosinophil response to different chemoattractant mediators such as platelet-activating factor (PAF acether) and N-formyl methionyl leucyl phenyl alanyl in vitro. Another anti-H1 drug, polaramine, did not show this effect at the same concentration. These findings suggest that cetirizine in addition to its antihistaminic effect could also play a direct inhibitory effect on eosinophil recruitment. Moreover, cetirizine was not toxic for eosinophils and did not induce degranulation, as shown by the absence of peroxidase release. Comparison between cetirizine and a PAF acether antagonist (BN 52021) suggested that cetirizine did not act by a PAF receptor-blocking activity.
Leprevost
C
C
Centre d'Immunologie et de Biologie Parasitaire, Unité mixte INSERM U167-CNRS 624, Institut Pasteur, Lille, France.
Capron
M
M
De Vos
C
C
Tomassini
M
M
Capron
A
A
D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D017332:Cetirizine; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D002744:Chlorpheniramine / Q000494:pharmacology; D004804:Eosinophils / Q000187:drug effects*; D005089:Exocytosis / Q000187:drug effects; D006801:Humans; D006919:Hydroxyzine / Q000031:analogs & derivatives* / Q000494:pharmacology; D066298:In Vitro Techniques; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000494:pharmacology
D010972:Platelet Activating Factor; D006919:Hydroxyzine; C018904:dexchlorpheniramine; D002744:Chlorpheniramine; D009240:N-Formylmethionine Leucyl-Phenylalanine; D007770:L-Lactate Dehydrogenase; D017332:Cetirizine